NCT00187148View on ClinicalTrials.gov

Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Human Immunodeficiency VirusHIV Infections
Interventions
BIOLOGICAL

EnvDNA

administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

St. Jude Children's Research Hospital

OTHER

NCT00187148 - Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter